Hybribio Biotech director to sell shares for personal financial needs

Guangdong Hybribio Biotech announced today that Mr. Xie Longxu, a worker representative director, plans to reduce his shareholding. Mr. Xie currently holds 375,456 shares, representing 0.0598% of the company's total share capital. The proposed reduction involves up to 93,864 shares, or approximately 0.0150% of the total share capital, and will not exceed 25% of his direct holdings.

The share reduction will occur through centralized bidding over a three-month period, commencing 15 trading days after the announcement date. This period will run from January 7, 2026, to April 6, 2026, excluding any periods prohibited by relevant laws and regulations. The reduction is attributed to personal financial needs, and the shares originated from equity incentives and capital reserve transfers.

The company stated that this plan will not lead to a change in control, nor will it adversely affect the company's governance structure or continuous operations. Pricing for the reduction will be determined by market prices at the time of sale. The company confirmed that Mr. Xie has not violated any prior commitments regarding share transfers.